Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.

Oncotarget - 27 Jun 2017

Chen Haibo, Luo Dingyuan, Zhang Lin, Lin Xiaofeng, Luo Qiuyun, Yi Hanjie, Wang Jing, Yan Xianglei, Li Baoxia, Chen Yuelei, Liu Xingguang, Zhang Hong, Liu Sheng, Qiu Miaozhen, Yang Dajun, Jiang Ningyi

Abstract excerpt

Dedifferentiated papillary thyroid cancer (DePTC) is characterized by aggressive growth, recurrence, distant metastasis, and resistance to radioactive iodine (RAI) therapy. DePTC is also accompanied by poor prognosis and high early-mortality. Nevertheless, most DePTC cells show intact p53 downstream functionality. In cells with wild-type p53, the murine double minute2 (MDM2) protein interacts with p53 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Papillary
Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Neoplasm Grading

Share to Protein Stability

Share to Proto-Oncogene Proteins c-mdm2

Share to Spiro Compounds

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 28498808
DOI: 10.18632/oncotarget.17398
PMCID: PMC5522123

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.PMID 28498808Read ↗

CircTP53 promotes the proliferation of thyroid cancer via targeting miR-1233-3p/MDM2 axisSemantic proximity Read ↗

SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathwaysSemantic proximity Read ↗

MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cellsSemantic proximity Read ↗

A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinomaSemantic proximity Read ↗

Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53.Semantic proximity Read ↗

USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responsesSemantic proximity Read ↗

Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells.Semantic proximity Read ↗

dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastropheSemantic proximity Read ↗

The PAX8 / PPARγ Fusion Oncogene as a Potential Therapeutic Target in Follicular Thyroid CarcinomaSemantic proximity Read ↗

Depletion of the human N<sup>α</sup>‐terminal acetyltransferase A induces p53‐dependent apoptosis and p53‐independent growth inhibitionSemantic proximity Read ↗

Targeting PEAK1 sensitizes anaplastic thyroid carcinoma cells harboring BRAFV600E to Vemurafenib by Bim upregulation.Semantic proximity Read ↗

Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.